Given that both genes are targets of GLI transcription factors [13, 22] we investigated whether their downregulation might be (at least partially) mediated by decreased GLI signaling: RNAseq data from various cancer cell lines suggested that treatment with NT1721 led to the downregulation of GLI1 and GLI2, which we then confirmed on the mRNA (Fig. 2b) and protein level (Fig. 2a) in Panc1 and Capan1 cells. The gene discussed is GLI1; the disease is cancer.